Please use a minimum of three unique search wordsOur search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Forsteo ® (teriparatide)
Forsteo® (teriparatide): Use With COVID-19 Vaccines
The use of vaccines against SARS-CoV-2 in patients treated with teriparatide [rDNA origin] injection has not been studied.
Severe acute respiratory syndrome coronavirus 2 is an emerging virus that has caused the recent COVID-19 pandemic.1 Recently, vaccines have been developed against SARS-CoV-2 and additional vaccines are expected to be available in the coming months.2
SARS-CoV-2 Vaccination With Teriparatide
The use of a SARS-CoV-2 vaccine in patients treated with teriparatide has not been studied by Lilly.
Decisions regarding the use of any vaccination, including SARS-CoV-2 vaccines, in patients treated with teriparatide should be made at the discretion of the prescribing physician using their best clinical judgment, and must be made by the clinician after careful consideration of risk factors of the patient as well as the risks and benefits of vaccination. Consultation with an infectious disease expert may be helpful in high-risk or emergency situations such as the current COVID-19 pandemic.
Vaccination Against COVID-19 Treatment Guidance in Patients With Osteoporosis
Recommendations for the management of patients with osteoporosis in relation to COVID-19 vaccination have been published by the International Osteoporosis Foundation.3
For the most current information please refer to Joint Guidance on COVID-19 Vaccination and Osteoporosis Management.3
Infectious Disease Resources for COVID-19
For current information on COVID-19, please refer to
Coronavirus disease (COVID-19) outbreak on the regional office EU WHO
1. Dong Y, Dai T, Wei Y, et al. A systematic review of SARS-CoV-2 vaccine candidates. Signal Transduct Target Ther. 2020;5(1):237. https://doi.org/10.1038/s41392-020-00352-y
2. Su Z, Wen J, McDonnell D, et al. Vaccines are not yet a silver bullet: the imperative of continued communication about the importance of COVID-19 safety measures. Brain Behav Immun Health. 2021;12:100204. https://doi.org/10.1016/j.bbih.2021.100204
3. Joint Guidance on COVID-19 Vaccination and Osteoporosis Management. The International Osteoporosis Foundation. March 9, 2021. Accessed March 26, 2021. https://www.osteoporosis.foundation/news/joint-guidance-covid-19-vaccination-and-osteoporosis-management-20210309-1500
4. Coronavirus and osteoporosis. Royal Osteoporosis Society. December 11, 2020. Accessed May 3, 2021. https://theros.org.uk/information-and-support/osteoporosis/coronavirus/
5. Coronavirus disease (COVID-19) outbreak. European web page of the World Health Organization. Accessed March 26, 2021. http://www.euro.who.int/en/health-topics/health-emergencies/coronavirus-covid-19
6. COVID-19. European Centre for Disease Prevention and Control. Accessed March 26, 2021. https://www.ecdc.europa.eu/en/novel-coronavirus-china
COVID-19 = coronavirus disease 2019
Lilly = Eli Lilly and Company
SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2
EU WHO = World Health Organization (European regional office)
ECDC = European Centre for Disease Prevention and Control
Date of Last Review: January 11, 2021